TerminatedPhase 2NCT01268280
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cytokinetics
- Principal Investigator
- Andrew Wolff, MD, FACCCytokinetics, Inc.
- Intervention
- Placebo(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2010 – 2012
Study locations (15)
- UCSF - Fresno, Fresno, California, United States
- University of California - Irvine, Orange, California, United States
- California Pacific Medical Center, San Francisco, California, United States
- Stanford University, Stanford, California, United States
- Hospital for Special Care, New Britain, Connecticut, United States
- The University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Neurocare Center for Research, Newton, Massachusetts, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Duke University, Durham, North Carolina, United States
- Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
- West Penn Allegheny Health System, Pittsburgh, Pennsylvania, United States
- Baylor College of Medicine, Houston, Texas, United States
- University of Texas Health Science Center, San Antonio, Texas, United States
- University of Virginia Health System, Charlottesville, Virginia, United States
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01268280 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.